NYSE:DPLO - Diplomat Pharmacy Stock Price, Price Target & More

$20.75 -0.30 (-1.43 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$20.75
Today's Range$20.59 - $21.14
52-Week Range$14.23 - $27.78
Volume415,923 shs
Average Volume689,238 shs
Market Capitalization$1.54 billion
P/E Ratio24.70
Dividend YieldN/A
Beta1.32

About Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy logoDiplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
SymbolNYSE:DPLO
CUSIPN/A
Phone888-720-4450

Debt

Debt-to-Equity Ratio0.70%
Current Ratio0.97%
Quick Ratio0.66%

Price-To-Earnings

Trailing P/E Ratio24.70
Forward P/E Ratio22.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.49 billion
Price / Sales0.34
Cash Flow$1.8395 per share
Price / Cash11.28
Book Value$10.88 per share
Price / Book1.91

Profitability

EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.35%
Return on Equity8.89%
Return on Assets4.47%

Miscellaneous

Employees2,419
Outstanding Shares74,070,000

How to Become a New Pot Stock Millionaire

Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy (NYSE:DPLO) posted its earnings results on Monday, February, 26th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.02. The firm earned $1.16 billion during the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The company's revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $0.08 earnings per share. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy updated its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share (EPS) guidance of $0.87-0.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.02. The company issued revenue guidance of $5.3-5.6 billion, compared to the consensus revenue estimate of $5.48 billion.

What price target have analysts set for DPLO?

11 Wall Street analysts have issued 12 month price objectives for Diplomat Pharmacy's shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $25.50 in the next year. View Analyst Ratings for Diplomat Pharmacy.

Who are some of Diplomat Pharmacy's key competitors?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
  • Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
  • Mr. Jeffrey G. Park, Interim CEO & Director (Age 46)
  • Mr. Joel Saban, Pres (Age 50)
  • Mr. Atul Kavthekar, CFO, Treasurer & Principal Accounting Officer

Has Diplomat Pharmacy been receiving favorable news coverage?

News headlines about DPLO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.16 on Accern's scale. They also assigned news coverage about the company an impact score of 47.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $20.75.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $1.54 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (DPLO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Diplomat Pharmacy (NYSE:DPLO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Diplomat Pharmacy in the last 12 months. Their average twelve-month price target is $25.50, suggesting that the stock has a possible upside of 22.89%. The high price target for DPLO is $35.00 and the low price target for DPLO is $17.00. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.452.452.502.17
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.50$25.50$20.5625$18.7813
Price Target Upside: 22.89% upside21.26% upside10.56% downside11.16% downside

Diplomat Pharmacy (NYSE:DPLO) Consensus Price Target History

Price Target History for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018BarclaysInitiated CoverageOverweight -> Overweight$27.00MediumView Rating Details
3/2/2018Deutsche BankUpgradeHold -> BuyHighView Rating Details
2/27/2018Needham & Company LLCSet Price TargetBuy$28.00HighView Rating Details
2/27/2018Wells FargoReiterated RatingMarket Perform$21.50 -> $25.00HighView Rating Details
2/27/2018Leerink SwannSet Price TargetOutperform -> Buy$32.00 -> $30.00HighView Rating Details
2/9/2018Lake Street CapitalInitiated CoverageBuy -> Buy$35.00HighView Rating Details
1/25/2018Credit Suisse GroupUpgradeUnderperform -> Neutral$28.00LowView Rating Details
1/24/2018MizuhoSet Price TargetHold$25.00LowView Rating Details
11/16/2017Robert W. BairdDowngradeOutperform -> Neutral$24.00 -> $18.00N/AView Rating Details
5/25/2017Bank of AmericaBoost Price TargetNeutral$17.00 -> $18.50LowView Rating Details
5/9/2017CowenBoost Price TargetMarket Perform$12.00 -> $17.00MediumView Rating Details
11/3/2016JPMorgan ChaseReiterated RatingHoldN/AView Rating Details
11/3/2016Raymond JamesReiterated RatingOutperform -> Market PerformN/AView Rating Details
11/3/2016CitigroupDowngradeMarket PerformN/AView Rating Details
11/3/2016Avondale PartnersDowngradeOutperform -> Market PerformN/AView Rating Details
5/19/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Diplomat Pharmacy (NYSE:DPLO) Earnings History and Estimates Chart

Earnings by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) Earnings Estimates

2018 EPS Consensus Estimate: $0.95
2019 EPS Consensus Estimate: $1.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.19$0.23$0.21
Q2 20182$0.23$0.24$0.24
Q3 20182$0.24$0.25$0.25
Q4 20182$0.24$0.27$0.26
Q1 20191$0.27$0.27$0.27
Q2 20191$0.29$0.29$0.29
Q3 20191$0.31$0.31$0.31
Q4 20191$0.34$0.34$0.34

Diplomat Pharmacy (NYSE DPLO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.23N/AView Earnings Details
2/26/2018Q4 2017$0.16$0.18$1.1668 billion$1.1551 billionViewListenView Earnings Details
11/6/2017Q3 2017$0.15$0.25$1.1602 billion$1.1250 billionViewN/AView Earnings Details
8/7/2017Q2 2017$0.15$0.25$1.1358 billion$1.1265 billionViewListenView Earnings Details
5/8/2017Q1 2017$0.15$0.19$1.0848 billion$1.0787 billionViewListenView Earnings Details
2/28/2017Q416$0.16$0.08$1.18 billion$1.1448 billionViewListenView Earnings Details
11/2/2016Q316$0.24$0.21$1.26 billion$1.1810 billionViewN/AView Earnings Details
8/9/2016Q216$0.21$0.23$1.12 billion$1.0890 billionViewN/AView Earnings Details
5/9/2016Q116$0.18$0.23$984.28 million$995.90 millionViewN/AView Earnings Details
2/29/2016Q415$0.20$0.21$969.70 million$987.00 millionViewListenView Earnings Details
11/3/2015Q315$0.16$0.26$928.86 million$946.90 millionViewN/AView Earnings Details
8/3/2015Q215$0.12$0.16$738.99 million$808.01 millionViewN/AView Earnings Details
5/11/2015Q115$0.08$0.09$629.60 million$625.00 millionViewListenView Earnings Details
3/2/2015Q414$0.06$0.08$603.70 million$603.67 millionViewN/AView Earnings Details
11/10/2014Q3 2014$0.15$595.53 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Diplomat Pharmacy (NYSE:DPLO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Diplomat Pharmacy (NYSE DPLO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 30.20%
Institutional Ownership Percentage: 63.73%
Insider Trading History for Diplomat Pharmacy (NYSE:DPLO)
Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE DPLO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Philip R. HagermanDirectorSell2,150,000$20.65$44,397,500.00View SEC Filing  
11/20/2017Atul KavthekarCFOBuy2,000$15.00$30,000.002,000View SEC Filing  
11/20/2017Jeffrey G ParkDirectorBuy3,000$15.46$46,380.007,640View SEC Filing  
11/20/2017Joel SabanPresidentBuy10,000$15.24$152,400.0012,000View SEC Filing  
9/15/2016Atheer A KaddisEVPSell20,000$30.12$602,400.0020,000View SEC Filing  
8/1/2016Atheer A KaddisEVPSell12,325$35.76$440,742.0012,325View SEC Filing  
7/1/2016Atheer A KaddisEVPSell12,325$35.04$431,868.0012,325View SEC Filing  
6/1/2016Atheer A KaddisEVPSell12,325$32.31$398,220.7512,325View SEC Filing  
5/2/2016Atheer A KaddisEVPSell12,325$30.17$371,845.2512,325View SEC Filing  
4/15/2016Atheer A KaddisEVPSell24,650$30.00$739,500.0024,650View SEC Filing  
2/12/2016Atheer A. KaddisEVPSell12,325$30.00$369,750.00View SEC Filing  
12/7/2015Philip R HagermanCEOSell2,300,000$33.60$77,280,000.00View SEC Filing  
12/1/2015Atheer A. KaddisSVPSell12,325$34.75$428,293.75View SEC Filing  
12/1/2015Gary W. KadlecPresidentSell30,000$34.93$1,047,900.00View SEC Filing  
11/3/2015Atheer A. KaddisSVPSell24,650$30.00$739,500.00View SEC Filing  
11/2/2015Gary W. KadlecPresidentSell30,000$28.03$840,900.00View SEC Filing  
10/1/2015Gary W. KadlecPresidentSell30,000$27.66$829,800.00View SEC Filing  
9/8/2015Atheer A. KaddisSVPSell12,325$37.42$461,201.50View SEC Filing  
9/1/2015Gary W. KadlecPresidentSell30,000$38.05$1,141,500.00View SEC Filing  
8/26/2015Sean WhelanCFOSell149,534$38.04$5,688,273.36142,530View SEC Filing  
3/25/2015David C DreyerDirectorBuy1,034$29.00$29,986.00View SEC Filing  
3/25/2015Jeffrey M RoweEVPSell600,000$29.00$17,400,000.00View SEC Filing  
3/25/2015Philip R HagermanCEOSell1,801,000$29.00$52,229,000.00View SEC Filing  
10/9/2014Atheer A KaddisSVPBuy4,000$13.00$52,000.00View SEC Filing  
10/9/2014Jeffrey M RoweEVPSell416,666$13.00$5,416,658.00View SEC Filing  
10/9/2014Philip R HagermanCEOSell2,916,666$13.00$37,916,658.00View SEC Filing  
10/9/2014Sean WhelanCFOBuy2,000$13.00$26,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Diplomat Pharmacy (NYSE DPLO) News Headlines

Source:
DateHeadline
Analyzing Express Scripts (ESRX) and Diplomat Pharmacy (DPLO)Analyzing Express Scripts (ESRX) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 15 at 11:30 PM
Diplomat Pharmacy (DPLO) Given Consensus Recommendation of "Hold" by BrokeragesDiplomat Pharmacy (DPLO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 8:17 AM
Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Sell"Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 14 at 11:26 PM
Edited Transcript of DPLO presentation 7-Mar-17 9:35pm GMTEdited Transcript of DPLO presentation 7-Mar-17 9:35pm GMT
finance.yahoo.com - April 12 at 9:34 AM
Zacks: Brokerages Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 BillionZacks: Brokerages Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 Billion
www.americanbankingnews.com - April 12 at 1:45 AM
 Brokerages Anticipate Diplomat Pharmacy (DPLO) Will Post Earnings of $0.22 Per Share Brokerages Anticipate Diplomat Pharmacy (DPLO) Will Post Earnings of $0.22 Per Share
www.americanbankingnews.com - April 10 at 11:16 PM
Reviewing Diplomat Pharmacy (DPLO) and Walgreens Boots Alliance (WBA)Reviewing Diplomat Pharmacy (DPLO) and Walgreens Boots Alliance (WBA)
www.americanbankingnews.com - April 9 at 7:14 AM
BidaskClub Upgrades Diplomat Pharmacy (DPLO) to "Buy"BidaskClub Upgrades Diplomat Pharmacy (DPLO) to "Buy"
www.americanbankingnews.com - April 8 at 7:00 PM
Diplomat Pharmacy (DPLO) Downgraded to "Buy" at BidaskClubDiplomat Pharmacy (DPLO) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 7 at 10:55 AM
1-800-PetMeds (PETS) versus Diplomat Pharmacy (DPLO) Head-To-Head Survey1-800-PetMeds (PETS) versus Diplomat Pharmacy (DPLO) Head-To-Head Survey
www.americanbankingnews.com - April 6 at 3:10 AM
Head-To-Head Contrast: HealthWarehouse.com (HEWA) and Diplomat Pharmacy (DPLO)Head-To-Head Contrast: HealthWarehouse.com (HEWA) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 5 at 9:30 AM
Notable Two Hundred Day Moving Average Cross - DPLONotable Two Hundred Day Moving Average Cross - DPLO
www.nasdaq.com - April 4 at 3:45 PM
Update: Lawsuit for Investors in Diplomat Pharmacy Inc. (NYSE: DPLO) Shares Announced by Shareholders FoundationUpdate: Lawsuit for Investors in Diplomat Pharmacy Inc. (NYSE: DPLO) Shares Announced by Shareholders Foundation
finance.yahoo.com - April 3 at 5:00 PM
Diplomat Pharmacy Sees Unusually Large Options Volume (DPLO)Diplomat Pharmacy Sees Unusually Large Options Volume (DPLO)
www.americanbankingnews.com - April 3 at 7:35 AM
Diplomat Pharmacy (DPLO) Given New $20.00 Price Target at MizuhoDiplomat Pharmacy (DPLO) Given New $20.00 Price Target at Mizuho
www.americanbankingnews.com - April 1 at 4:16 PM
Needham & Company LLC Boosts Diplomat Pharmacy (DPLO) Price Target to $24.00Needham & Company LLC Boosts Diplomat Pharmacy (DPLO) Price Target to $24.00
www.americanbankingnews.com - April 1 at 10:28 AM
Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Hold"Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 31 at 11:34 PM
Diplomat Pharmacy (DPLO) versus Restaurant Brands International (QSR) Head-To-Head SurveyDiplomat Pharmacy (DPLO) versus Restaurant Brands International (QSR) Head-To-Head Survey
www.americanbankingnews.com - March 30 at 5:20 PM
Analyzing BJ's Restaurants (BJRI) and Diplomat Pharmacy (DPLO)Analyzing BJ's Restaurants (BJRI) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - March 21 at 9:30 PM
Diplomat Pharmacy Inc (DPLO) Given Average Recommendation of "Hold" by BrokeragesDiplomat Pharmacy Inc (DPLO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 21 at 8:36 AM
Diplomat to Present at 2018 Needham & Company Healthcare ConferenceDiplomat to Present at 2018 Needham & Company Healthcare Conference
finance.yahoo.com - March 19 at 4:49 PM
Amazon and others might be eyeing this pharmacy, analyst says ... - MarketWatchAmazon and others might be eyeing this pharmacy, analyst says ... - MarketWatch
www.marketwatch.com - March 15 at 8:48 AM
Amazon and others might be eyeing this pharmacy, analyst says - MarketWatchAmazon and others might be eyeing this pharmacy, analyst says - MarketWatch
www.marketwatch.com - March 14 at 6:26 PM
Diplomat to Present at 2018 Barclays Global Healthcare ConferenceDiplomat to Present at 2018 Barclays Global Healthcare Conference
finance.yahoo.com - March 13 at 6:50 PM
Amazon and others might be eyeing this pharmacy, analyst saysAmazon and others might be eyeing this pharmacy, analyst says
finance.yahoo.com - March 13 at 9:03 AM
Diplomat Pharmacy Inc (DPLO) Director Philip R. Hagerman Sells 2,150,000 SharesDiplomat Pharmacy Inc (DPLO) Director Philip R. Hagerman Sells 2,150,000 Shares
www.americanbankingnews.com - March 12 at 7:21 PM
Diplomat Pharmacy (DPLO) Coverage Initiated by Analysts at BarclaysDiplomat Pharmacy (DPLO) Coverage Initiated by Analysts at Barclays
www.americanbankingnews.com - March 9 at 12:43 AM
Dance Biopharm Elects Benjamin Wolin to Board of DirectorsDance Biopharm Elects Benjamin Wolin to Board of Directors
finance.yahoo.com - March 8 at 6:00 PM
Zacks: Analysts Anticipate Diplomat Pharmacy Inc (DPLO) Will Post Earnings of $0.23 Per ShareZacks: Analysts Anticipate Diplomat Pharmacy Inc (DPLO) Will Post Earnings of $0.23 Per Share
www.americanbankingnews.com - March 7 at 7:08 PM
Diplomat Pharmacy Filings Illustrate Competitive Pressure On AmerisourceBergenDiplomat Pharmacy Filings Illustrate Competitive Pressure On AmerisourceBergen
finance.yahoo.com - March 7 at 5:52 PM
Financial Review: Diplomat Pharmacy (DPLO) vs. Acadia Healthcare (ACHC)Financial Review: Diplomat Pharmacy (DPLO) vs. Acadia Healthcare (ACHC)
www.americanbankingnews.com - March 5 at 1:52 PM
Blog Exposure - Rigel Pharma to Exhibit 2 Fostamatinib Presentations at 4th Biennial Summit of Thrombosis & Hemostasis Societies of North AmericaBlog Exposure - Rigel Pharma to Exhibit 2 Fostamatinib Presentations at 4th Biennial Summit of Thrombosis & Hemostasis Societies of North America
finance.yahoo.com - March 5 at 8:55 AM
Diplomat Pharmacy (DPLO) Upgraded at Deutsche BankDiplomat Pharmacy (DPLO) Upgraded at Deutsche Bank
www.americanbankingnews.com - March 3 at 3:24 PM
Diplomat Pharmacy Inc (DPLO) Holdings Boosted by State of Wisconsin Investment BoardDiplomat Pharmacy Inc (DPLO) Holdings Boosted by State of Wisconsin Investment Board
www.americanbankingnews.com - March 1 at 6:10 PM
William Blair Comments on Diplomat Pharmacy Incs FY2019 Earnings (DPLO)William Blair Comments on Diplomat Pharmacy Inc's FY2019 Earnings (DPLO)
www.americanbankingnews.com - March 1 at 2:50 PM
Investors Research Corp Acquires New Position in Diplomat Pharmacy Inc (DPLO)Investors Research Corp Acquires New Position in Diplomat Pharmacy Inc (DPLO)
www.americanbankingnews.com - March 1 at 2:06 PM
Diplomat Pharmacy Inc to Post Q1 2018 Earnings of $0.23 Per Share, Leerink Swann Forecasts (DPLO)Diplomat Pharmacy Inc to Post Q1 2018 Earnings of $0.23 Per Share, Leerink Swann Forecasts (DPLO)
www.americanbankingnews.com - March 1 at 8:36 AM
Diplomat Pharmacy Thinks Its Strategy Is a "Huge Game Changer"Diplomat Pharmacy Thinks Its Strategy Is a "Huge Game Changer"
www.msn.com - February 28 at 5:32 PM
Diplomat Pharmacy Thinks Its Strategy Is a "Huge Game Changer"Diplomat Pharmacy Thinks Its Strategy Is a "Huge Game Changer"
finance.yahoo.com - February 28 at 5:32 PM
William Blair Weighs in on Diplomat Pharmacy Incs Q1 2018 Earnings (DPLO)William Blair Weighs in on Diplomat Pharmacy Inc's Q1 2018 Earnings (DPLO)
www.americanbankingnews.com - February 28 at 8:26 AM
Diplomat Pharmacy (DPLO) PT Set at $30.00 by Leerink SwannDiplomat Pharmacy (DPLO) PT Set at $30.00 by Leerink Swann
www.americanbankingnews.com - February 27 at 11:56 PM
Wells Fargo & Co Raises Diplomat Pharmacy (DPLO) Price Target to $25.00Wells Fargo & Co Raises Diplomat Pharmacy (DPLO) Price Target to $25.00
www.americanbankingnews.com - February 27 at 11:56 PM
Diplomat Pharmacy (DPLO) Given a $28.00 Price Target at Needham & Company LLCDiplomat Pharmacy (DPLO) Given a $28.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - February 27 at 7:22 PM
Why Diplomat Pharmacy Sank TodayWhy Diplomat Pharmacy Sank Today
finance.yahoo.com - February 27 at 5:28 PM
Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance - PR Newswire (press release)Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance - PR Newswire (press release)
www.prnewswire.com - February 27 at 8:54 AM
Diplomat Pharmacys (DPLO) CEO Jeff Park on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaDiplomat Pharmacy's (DPLO) CEO Jeff Park on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 27 at 8:54 AM
Diplomat Pharmacy (DPLO) Posts  Earnings Results, Beats Expectations By $0.02 EPSDiplomat Pharmacy (DPLO) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - February 26 at 9:14 PM
Diplomat Pharmacy Q4 Earnings PreviewDiplomat Pharmacy Q4 Earnings Preview
finance.yahoo.com - February 26 at 5:21 PM
Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 GuidanceDiplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance
finance.yahoo.com - February 26 at 5:21 PM
Diplomat Pharmaceuticals posts 4Q profitDiplomat Pharmaceuticals posts 4Q profit
finance.yahoo.com - February 26 at 5:21 PM

SEC Filings

Diplomat Pharmacy (NYSE:DPLO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Diplomat Pharmacy (NYSE:DPLO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Diplomat Pharmacy (NYSE DPLO) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.